35
Participants
Start Date
February 14, 2020
Primary Completion Date
May 31, 2027
Study Completion Date
November 30, 2027
bb1111
Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Montefiore Medical Center, The Bronx
Children's National Hospital, Washington D.C.
Virginia Commonwealth University (VCU), Richmond
Duke University, Durham
University of Alabama, Birmingham
University of Minnesota, Minneapolis
Baylor College of Medicine/Texas Children's Hospital, Houston
Tufts Medical Center, Boston
Hackensack University Medical Center, Hackensack
Lead Sponsor
Genetix Biotherapeutics Inc.
INDUSTRY